Skip to main content
logo
KalVista Pharmaceuticals, Inc. (KALV)
Jun 11, 2026 - KALV was delisted (reason: acquired by Chiesi Group)
27.00
+0.01 (0.04%)
Inactive · Last trade price on Jun 10, 2026

KalVista Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY FY 2023
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Revenue
114.4873.62----
Revenue Growth
------
Gross Profit
58.4718.94-71.71-86.17--80.28
Operating Income
-140-166.27-188-140.45--110.87
Net Income
-135.94-164.29-183.44-126.64--92.91
Earnings Per Share
-2.51-3.05-3.69-3.44--3.33
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY FY 2023
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Cash & Investments
285.03300.21220.62210.4-149.38
Total Debt
284.31284.21112.197.32-8.23
Net Cash (Debt)
0.7216.01108.43203.08-141.14
Net Cash Growth
-99.34%-85.24%-46.61%---10.68%
Net Cash Per Share
0.010.302.185.52-5.06

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY FY 2023
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Operating Cash Flow
-89.32-122.43-152.91-89.23--75.26
Capital Expenditures
-2.39-2.56-0.43-0.04--1.2
Free Cash Flow
-91.71-124.99-153.34-89.27--76.46
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY FY 2023
Period EndingMar '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
Gross Margin
51.07%25.73%----
Operating Margin
-122.30%-225.86%----
Pretax Margin
-123.81%-225.27%----
Profit Margin
-118.74%-223.16%----
FCF Margin
-80.11%-169.79%----

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY FY 2023
Period EndingAug '26 Dec '25 Apr '25 Apr '24 Mar '24 Apr '23
PS Ratio
12.5611.09----